Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBPP) Accounts Payables (2016 - 2025)

Regen BioPharma (RGBPP) has disclosed Accounts Payables for 12 consecutive years, with $11024.0 as the latest value for Q4 2025.

  • On a quarterly basis, Accounts Payables fell 69.38% to $11024.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $11024.0, a 69.38% decrease, with the full-year FY2025 number at $1714.0, down 94.22% from a year prior.
  • Accounts Payables was $11024.0 for Q4 2025 at Regen BioPharma, up from $1714.0 in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $1.3 million in Q3 2021 to a low of $1714.0 in Q3 2025.
  • A 5-year average of $222961.0 and a median of $32995.5 in 2021 define the central range for Accounts Payables.
  • Biggest YoY gain for Accounts Payables was 3823.06% in 2022; the steepest drop was 97.73% in 2022.
  • Regen BioPharma's Accounts Payables stood at $32288.0 in 2021, then surged by 3823.06% to $1.3 million in 2022, then crashed by 96.51% to $44183.0 in 2023, then decreased by 18.51% to $36005.0 in 2024, then crashed by 69.38% to $11024.0 in 2025.
  • Per Business Quant, the three most recent readings for RGBPP's Accounts Payables are $11024.0 (Q4 2025), $1714.0 (Q3 2025), and $30477.0 (Q2 2025).